Delving into the Latest Updates on AHB-171 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

AHB-171

Target-

Action-

Mechanism-

Therapeutic Areas

Infectious DiseasesDigestive System Disorders

Active Indication

Hepatitis B, Chronic

Inactive Indication-

Originator Organization

Ausper Biopharma Co., Ltd.

Active Organization

Ausper Biopharma Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of AHB-171 in participants with chronic hepatitis B (CHB). Study advancement to subsequent parts/cohorts will require satisfactory interim reviews of available cumulative safety data by the Safety Review Committees (SRC), using the safety criteria and review procedures described in the protocol.

Start Date06 Jul 2026

Sponsor / Collaborator

Ausper Biopharma Co., Ltd.

NCT07511218

/ RecruitingPhase 1

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AHB - 171 Injection in Healthy Participants (HP) and Chronic Hepatitis B(CHB) Participants

The goal of this clinical trial is to evaluate the safety, tolerability, immunogenicity and Pharmacokinetics (PK) characteristics of AHB-171 Injection in healthy participants (Part A) and participants with chronic hepatitis B (CHB, Part B), and assess its preliminary efficacy in CHB participants.

Start Date13 Apr 2026

Sponsor / Collaborator

Ausper Biopharma Co., Ltd.

100 Clinical Results associated with AHB-171

Login to view more data

100 Translational Medicine associated with AHB-171

Login to view more data

100 Patents (Medical) associated with AHB-171

Login to view more data

100 Deals associated with AHB-171

Login to view more data